The Lab2Go project, co-funded by the European Commission, is a study to determine the value of a point-of-care testing system for measuring cardiac Troponin-I (cTnI) at the patients’ bedside as an aid in the diagnosis of patients with the indications of a Myocardial Infarction (MI). A blood sample can be taken and tested by the doctor, nurse or paramedic to provide cTnI measurement during clinical assessment, rather than having to wait for laboratory results.
The goal of the Lab2Go project is to bring a (handheld) Point-of-Care system to the next level of maturity by demonstrating it in real user environments. The aim is to have a solution available at the end of the project which meets the targeted system specifications, is accepted by the intended users and is ready for clinical validation. The cTnI marker is the first demonstrator of a series of acute (cardiac) markers that will be developed for the system.
The Point-of-Care system that will be demonstrated is referred to as the Minicare system - an innovative biophotonics based technology that employs a surface sensitive optical detection technique to determine a biomarker concentration in blood. The system is designed to enable various biomarkers to be measured in whole blood within 10 minutes at lab-quality precision.
The Lab2Go project is a European Union funded multicenter Research and Development project (project nr. 621035) conducted at six hospitals in the European Union bringing together a pan-European consortium of leading companies, universities, hospitals and healthcare suppliers. Initiated in 2014, the 2-½ year program will address the analytical and clinical performance of the system, the user acceptance of the system and gather healthcare economics data.